Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead vaccine candidate, PIKA rabies vaccine, which is an innovative rabies vaccine independently developed by YishengRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological therapeutics, today announced the completion of Phase I clinical trial of PIKA Hepatitis B vaccine, an investigational vaccine designed to provide both prophylactic and therapeutic benefits against hepatitis B virus infection. This vaccine candidate is a proprietary productRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead product candidate, YS-ON-001, for the treatment of hepatocellular carcinoma. YS-ON-001 is a promising biological product withRead More

Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of biological vaccines and pharmaceutical products, and the United States Army Medical Research Institute of Infectious Diseases  (“USAMRIID”) today announced preliminary positive animal results of a virus-like particle (VLP)-based vaccine in combination with PIKA adjuvant,  a Toll-Like ReceptorRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced positive topline results from Phase I clinical trial of PIKA rabies vaccine, an investigational vaccine designed to provide accelerated immune response against post-exposure rabies virus infection.  PIKA rabies vaccine is an innovative rabies vaccineRead More

Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced that Yisheng US Biopharma Inc., its wholly owned research subsidiary, has entered into a collaboration with the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”) to develop a new vaccine against the EbolaRead More

Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide. This project was named a “National Key Medicine Innovation” inRead More